Inovio Stock Financials


USD 1.98  0.06  3.13%   

Inovio Pharmaceuticals Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 520.92 Million. Working Capital is expected to rise to about 412.9 M this year, although the value of Net Income Per Employee will most likely fall to (1 M).
With this module, you can analyze Inovio financials for your investing period. You should be able to track the changes in Inovio Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Inovio Most Recent Estimates

EPS Estimate Next Quarter
Diluted Eps
EPS Estimate Current Year
EPS Estimate Next Year
EPS Estimate Current Quarter
Earnings Share
Understanding current and past Inovio Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Inovio Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Inovio Pharmaceuticals' assets may result in an increase in income on the income statement.


1.82 Million

The financial analysis of Inovio Pharmaceuticals is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Inovio Pharmaceuticals includes many different criteria found on its balance sheet. For example, investors should never minimize Inovio Pharmaceuticals' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Inovio Pharmaceuticals' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Inovio Pharmaceuticals.

Inovio Pharmaceuticals Cash

Chance Of Financial Distress
Less than 23
Inovio Pharmaceuticals has less than 23 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Inovio Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Inovio Pharmaceuticals' official financial statements usually reflect Inovio Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Inovio Pharmaceuticals. For example, before you start analyzing numbers published by Inovio accountants, it's critical to develop an understanding of what Inovio Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Inovio Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inovio Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Inovio Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inovio Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Inovio Pharmaceuticals' management to manipulate its earnings.

Inovio Pharmaceuticals Company Summary

Inovio Pharmaceuticals competes with Anheuser Busch, and Northwest Healthcare. Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus , cancer, and infectious diseases. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Inovio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 317 people.
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001055726
RegionNorth America
Business Address660 West Germantown
IndustryHealth Care
BenchmarkNYSE Composite
Phone267 440 4200
CurrencyUSD - US Dollar
You should never invest in Inovio Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Inovio Stock, because this is throwing your money away. Analyzing the key information contained in Inovio Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Inovio Pharmaceuticals Key Financial Ratios

Generally speaking, Inovio Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Inovio Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Inovio Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Inovio Pharmaceuticals reports annually and quarterly.

Inovio Pharmaceuticals Key Balance Sheet Accounts

201720182019202020212022 (projected)
Receivables6 M3.32 M700.07 K18.56 M5.47 M5.15 M
Accounts Payable8.49 M11.02 M7.65 M1.47 M24.76 M26.72 M
Total Assets187.24 M131.11 M143.95 M539.77 M495.94 M535.09 M
Current Assets138.36 M87.81 M94.2 M471.17 M448.44 M483.85 M
Assets Non Current48.88 M43.3 M49.75 M68.6 M47.5 M49.73 M
Cash and Equivalents23.79 M23.69 M22.2 M250.73 M71.14 M57.99 M
Deferred Revenue1.57 M407.94 K225.69 K125.84 K85.99 K88.25 K
Shareholders Equity142.39 M86.94 M3.44 M461.14 M399.67 M431.22 M
Investments115.03 M66.94 M73.65 M165.81 M334.08 M360.45 M
Investments Current103.64 M57.54 M67.34 M160.91 M330.17 M356.24 M
Total Liabilities44.85 M44.18 M140.52 M78.63 M96.27 M103.87 M
Current Liabilities35.41 M35.3 M31.99 M41.71 M65.74 M70.93 M
Tax Liabilities175.64 K174.79 K24.77 K32.05 K28.84 K29.6 K

Inovio Pharmaceuticals Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Inovio Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Consolidated Income(88.21 M)(96.97 M)(120.55 M)(167.47 M)(303.66 M)(311.65 M)
Gross Profit42.22 M30.48 M4.11 M7.41 M1.77 M1.82 M
Net Income(88.21 M)(96.97 M)(119.36 M)(166.41 M)(303.66 M)(311.65 M)
Operating Expenses125.86 M124.57 M115.22 M131.49 M302.99 M326.91 M
Operating Income(84.64 M)(94.09 M)(111.11 M)(124.08 M)(301.22 M)(309.14 M)
Revenues42.22 M30.48 M4.11 M7.41 M1.77 M1.82 M

Inovio Pharmaceuticals Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Inovio Pharmaceuticals. It measures of how well Inovio is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Inovio Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Inovio had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Inovio Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(10.29 M)(2.09 M)(987.93 K)(1.52 M)(1.23 M)(1.33 M)
Depreciation Amortization and Accretion3.47 M5 M5.52 M4.63 M4.73 M4.39 M
Net Cash Flow or Change in Cash and Cash Equivalents4.65 M(92.95 K)(1.5 M)228.53 M(179.58 M)(184.31 M)
Issuance Purchase of Equity Shares94.35 M29.23 M9.2 M466.76 M216.11 M233.17 M
Net Cash Flow from Financing95.69 M31.04 M105.4 M465.28 M211.5 M228.2 M
Net Cash Flow from Investing(27.83 M)42.42 M(9.04 M)(58.8 M)(175.34 M)(179.96 M)
Net Cash Flow Investment Acquisitions and Disposals(18.54 M)44.5 M(8.06 M)(93.23 M)(174.11 M)(178.7 M)
Net Cash Flow from Operations(63.21 M)(73.55 M)(97.85 M)(177.98 M)(215.71 M)(221.39 M)
Share Based Compensation13.07 M10.65 M10.9 M15.65 M26.34 M28.42 M

Inovio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Inovio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Inovio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inovio Pharmaceuticals competition to find correlations between indicators driving Inovio Pharmaceuticals's intrinsic value. More Info.
Inovio Pharmaceuticals is currently regarded as number one stock in number of employees category among related companies. It is currently regarded as number one stock in target price category among related companies fabricating about  0.01  of Target Price per Number of Employees. The ratio of Number of Employees to Target Price for Inovio Pharmaceuticals is roughly  140.89 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Inovio Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inovio Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inovio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Inovio Pharmaceuticals Systematic Risk

Inovio Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Inovio Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Inovio Pharmaceuticals correlated with the market. If Beta is less than 0 Inovio Pharmaceuticals generally moves in the opposite direction as compared to the market. If Inovio Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Inovio Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Inovio Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Inovio Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.

About Inovio Pharmaceuticals Financials

What exactly are Inovio Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Inovio Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Inovio Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Inovio Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Inovio Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inovio Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Inovio Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Inovio has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Inovio Pharmaceuticals Thematic Clasifications

Inovio Pharmaceuticals is part of several thematic ideas from Cancer Fighters to Aggressive Defence. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Cancer Fighters Idea
Cancer FightersView
Aggressive Defence Idea
Aggressive DefenceView

Inovio Pharmaceuticals December 3, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Inovio Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Inovio Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Inovio Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Inovio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Inovio Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio(0.037432)
Maximum Drawdown26.28
Value At Risk(8.70)
Potential Upside7.93
Please see Risk vs Return Analysis. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for analysis

When running Inovio Pharmaceuticals price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
494 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Inovio Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.